Antibody–Drug Conjugates and Cancer Immunotherapy
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".
Deadline for manuscript submissions: 25 October 2024 | Viewed by 218
Special Issue Editor
Interests: clinical and translational research; mechanisms of resistance to anticancer drugs; immunotherapy, non-invasive biomarkers
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Antibody–drug conjugates (ADCs) are powerful anticancer agents designed for target delivery of cytotoxic molecules. Several studies indicate that ADCs have immunostimulatory properties through different mechanisms, including macrophage reprogramming and T memory cell generation. These observations led to growing interest in the development of ADCs specifically designed to boost the immune response through the delivery of immuno-stimulant payloads or by targeting the tumor microenvironment. Despite this, many questions remain open: can immuno-stimulant ADCs induce a response in "cold tumors", refractory to immune checkpoint inhibitors? Can ADCs revert immunotherapy resistance? Do ADCs and immunotherapy agents have a synergistic effect? Is there an optimal sequence for treatment in cancers with known sensitivity to ADCs and immunotherapy? The publication of a Special Issue may facilitate solutions to some of these questions and support the development of effective treatment strategies for cancer patients.
Dr. Sofia Genta
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- ADC
- immunotherapy
- cancer
- drug resistance
- tumor microenvironment
